Advanced Medical Solutions Grp PLC
09 March 2006
For Immediate Release 9th March 2006
Advanced Medical Solutions Group plc
('AMS' or 'the Company')
Strategic partnership with Kimberly-Clark for technology
to reduce the risk of skin flora contamination throughout a surgical procedure
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global
healthcare technology company, today announces that it has entered into an
exclusive global agreement with Kimberly-Clark Health Care for the marketing and
distribution of a novel application of its medical adhesives technology to help
control the risk of skin flora contamination throughout a surgical procedure, a
key factor in the development of surgical site infections (SSIs). Kimberly-Clark
* InteguSeal* Microbial Sealant, a first-in-class microbial barrier that helps
protect surgical incisions from bacterial migration, was launched today in
Europe and other geographies. Product testing and preliminary user evaluations
in a variety of procedures have been very positive.
Surgical site infections occur in 2-5% of all surgical procedures. They can
lead to serious complications and increased morbidity to the patient and
significant incremental costs to health care providers. It is generally accepted
that contamination by the patient's endogenous skin flora is a key factor in the
development of surgical site infection and despite standard preventative steps,
SSIs remain an issue of concern.
AMS has developed an innovative film-forming solution that bonds to the skin
sealing off the spaces where bacteria can grow. Based upon patented
cyanoacrylate technology, Kimberly-Clark* InteguSeal* immobilises endogenous
pathogens thereby reducing the risk of skin flora contamination.
A novel applicator has been developed that allows InteguSeal* Microbial Sealant
to be effectively applied even on irregular and contoured areas of the body,
such as shoulders and knees, which are generally difficult to drape. Easy to
apply and fast-drying, Kimberly-Clark* InteguSeal* can be used in conjunction
with a variety of preparatory treatments and surgical products such as
electrocautery, sutures, staples and wound adhesives. Kimberly-Clark* InteguSeal
* Microbial Sealant has been CE marked for sale in the EU, cleared for sale in
other geographies and is currently under review for market clearance in the
United States.
Under the terms of the agreement announced today, Kimberly-Clark Health Care
will have exclusive rights to market and sell this new technology in all global
markets. Atlanta based Kimberly-Clark Health Care is an over $1 billion
business unit within the global Kimberly-Clark Corporation. It manufactures and
markets a wide range of surgical products and is a leader in several medical
device categories.
Commenting on today's announcement, Joanne Bauer, President of Kimberly-Clark
Health Care stated:
'This product further enhances our position as a leading global provider of
innovative and technologically advanced medical devices. We are excited by the
opportunity that the AMS technology offers in delivering our strategy of
expanding our presence in the Operating Room with a platform of products for
infection control.'
Dr. Don Evans, Chief Executive of AMS added:
'We are delighted to have Kimberly-Clark Health Care as our marketing and
distribution partner for this technology. Their strong global presence and focus
on the Operating Room makes them an ideal partner for rapid commercialisation of
this product.'
-ENDS-
For further information, please contact:
Advanced Medical Solutions Group plc Tel : +44 (0) 1606 545508
Don Evans, Chief Executive
Mary Tavener, Finance Director
www.admedsol.com
Buchanan Communications Tel: +44 (0) 20 7466 5000
Mark Court, Mary-Jane Johnson
Notes to Editors:
Advanced Medical Solutions is a leading company in the development and
manufacture of products for the $13 billion global woundcare market.
Founded in 1991 and currently quoted on AIM, Advanced Medical Solutions is
focused on the design, development and manufacture of innovative and
technologically advanced products for woundcare and other medical applications.
In-house natural and synthetic polymer technology is used to provide advanced
wound dressings based on the moist healing principle. AMS's resources ensure a
unique position as a vertically integrated 'one stop shop' to provide all
categories of moist wound healing products. The Company has the capability to
move from product design and development through to production and delivery
ready for distribution into customer markets.
The acquisition of MedLogic in 2002 has brought AMS products and technology in
cyanoacrylate based tissue adhesives that offer benefits over sutures and
staples for closing wounds sold direct to hospitals or through distributors.
AMS's technology and products currently serve the majority of the key global
markets and strategic partners.
Kimberly-Clark in the Healthcare Environment
Around the world, medical professionals turn to Kimberly-Clark for a wide
portfolio of solutions that improve the health, hygiene and well-being of their
patients and staff. As part of their healing mission, caregivers rely on
Kimberly-Clark to deliver clinical solutions and educational resources that they
can depend on to prevent, diagnose and manage a wide variety of
healthcare-associated infections. This over $1 billion global enterprise of
Kimberly-Clark Corporation holds the No. 1 and No. 2 market share positions in
several categories including infection control solutions, surgical solutions,
pain management and digestive health. And throughout the care continuum,
patients and staff alike trust Kimberly-Clark* medical supplies and devices,
KLEENEX* tissues, KIMBERLY-CLARK* professional skin care products, and SCOTT*
towels for day-to-day needs. For more information, please visit http://
www.kchealthcare.com.
* Registered Trademark or Trademark of Kimberly-Clark Worldwide, Inc. (c) 2006
KCWW.
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.